Fulminant hepatitis as an immune-related adverse event after nivolumab treatment

Pathol Int. 2019 Jul;69(7):434-436. doi: 10.1111/pin.12812. Epub 2019 Jul 8.

Authors

Osamu Inamori¹, Aya Miyagawa-Hayashino¹, Akihisa Ueno², Fumiya Hongo², Yuta Sonobe¹, Tomohito Hojo¹, Eiichi Konishi¹

Affiliations

¹ Department of Surgical Pathology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
² Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

PMID: 31286591
DOI: 10.1111/pin.12812

No abstract available

Keywords: fulminant hepatitis; immune-related adverse event; nivolumab; treatment.

Publication types

Case Reports
Letter

MeSH terms

Aged, 80 and over
Diabetes Mellitus, Type 1 / drug therapy
Female
Humans
Massive Hepatic Necrosis / chemically induced*
Massive Hepatic Necrosis / pathology
Nivolumab / adverse effects*
Treatment Outcome

Substances

Nivolumab